Monopar reports Q2 net loss $1.7M, initiates 1-for-5 reverse split to regain Nasdaq compliance

Monopar Therapeutics

Net loss for Q2 2024 was $1.7M ($0.10/sh) vs $2.2M ($0.16/sh) in Q2 2023; cash $7.1M sufficient through Aug 31, 2025.
MNPR-101-Zr Phase 1 imaging trial initiated and enrolling; MNPR-101-RIT therapeutic trial on track to start Q4 2024.
1-for-5 reverse stock split effective Aug 12, 2024; shares reduce from ~17.6M to ~3.5M to regain Nasdaq compliance.
Company winding down camsirubicin and MNPR-202 programs to focus on radiopharmaceutical platform.
Needs additional funding within 12 months to further advance radiopharma programs.

item 2.02 item 3.03 item 5.03 item 5.07 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.